Here are five quick facts about the update:
• Integra LifeSciences now has a “Buy” consensus rating
• The average 12-month price target is $63.71.
• Argus raised the price total from $61 to $72 on March 25.
• Zacks reiterated “neutral” and set the price target at $63 last month.
• The company has a market cap of $2 billion and 50 day moving average of $59.
The company reported revenue at $252 million for the most recent quarter, up 14.2 percent year-over-year. The analysts predict the company will post $3.17 earnings per share in the current fiscal year.
More articles on orthopedic devices:
12 observations on implant materials for the next generation
16 spine devices receive FDA 510(k) clearance in March
Zimmer voluntarily recalls knee device
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
